期刊文献+

蛋白质乙酰化对宰后肉品质调控的研究进展 被引量:3

The regulation of protein acetylation on the postmortem meat quality
下载PDF
导出
摘要 蛋白质乙酰化是一种动态、可逆的蛋白质翻译后修饰方式,它是连接乙酰辅酶A代谢与机体细胞信号转导重要的蛋白质翻译后修饰类型,可以调节基因表达、代谢、细胞凋亡、钙信号传导、蛋白质水解、肌肉收缩以及疾病预防。宰后肌肉的糖酵解、肌肉收缩以及细胞凋亡对肉品质的形成具有重要影响,因此,蛋白质乙酰化可能通过调节宰后肌肉的糖酵解、肌肉收缩与细胞凋亡从而调控肉品质。该文通过综述近年来蛋白质乙酰化对糖酵解、肌肉收缩及细胞凋亡调控的研究进展,阐明了蛋白质乙酰化可能对肉品质的调控具有重要影响,并对未来研究进行了展望。 Protein acetylation is a dynamic and reversible protein post-translational modification,which is a pivotal protein post-translational modification linking acetyl-CoA metabolism and cell signal transduction.Protein acetylation is involved in many processes such as gene expression,energy metabolism,cell apoptosis,calcium signaling,protein hydrolysis,muscle contraction and disease.Glycolysis,muscle contraction and cell apoptosis of postmortem muscles have vital effects on meat quality formation.Therefore,the protein acetylation may regulate meat quality by regulating postmortem muscle glycolysis,muscle contraction and cell apoptosis.In this context,the influence of protein acetylation on glycolysis,muscle contraction and cell apoptosis were reviewed,and the possible regulations of protein acetylation on meat quality were discussed.Finally,some perspectives on the future researches of protein acetylation were also been given.
作者 田铸 师希雄 张攀高 郭兆斌 余群力 王建忠 TIAN Zhu;SHI Xixiong;ZHANG Pangao;GUO Zhaobin;YU Qunli;WANG Jianzhong(College of Food Science and Engineering,Gansu Agricultural University,Lanzhou 730070,China)
出处 《食品与发酵工业》 CAS CSCD 北大核心 2021年第4期269-274,共6页 Food and Fermentation Industries
基金 国家自然科学基金项目(31760436) 甘肃省高等学校创新能力提升项目(2020A-049) 青年研究生指导教师扶持基金项目(GAU-QNDS-201716)。
关键词 蛋白质乙酰化 糖酵解 肌肉收缩 细胞凋亡 肉品质 protein acetylation glycolysis muscle contraction cell apoptosis meat quality
  • 相关文献

参考文献7

二级参考文献56

  • 1Matthias Ocker.Deacetylase inhibitors-focus on non-histone targets and effects[J].World Journal of Biological Chemistry,2010,1(5):55-61. 被引量:11
  • 2HU Jia GUO Yanting LI Yanme.Research progress in protein post-translational modification[J].Chinese Science Bulletin,2006,51(6):633-645. 被引量:4
  • 3Blum KA,Lozanski G,Byrd JC.Adult Burkitt leukemia and lymphoma.Blood,2004;104(10):3009-3020.
  • 4Bosch F,Lopez-Guillermo A,Campo E,et al.Mantle celllymphoma:presenting features,response to therapy,and progno-stic factors.Cancer,1998;82(3):567-575.
  • 5Prince HM,Bishton MJ,Harrison SJ.Clinical studies of histonedeacetylase inhibitors.Clin Cancer Res,2009;15(12):3958-3969.
  • 6Cress WD,Seto E.Histone deacetylases,transcriptional control,and cancer.J Cell Physiol,2000;184(1):1-16.
  • 7Peart MJ,Tainton KM,Ruefli AA,et al.Novel mechanisms ofapoptosis induced by histone deacetylase inhibitors.Cancer Res,2003;63(15):4460-4471.
  • 8Kavanaugh SM,White LA,Kolesar JM.Vorinostat:a noveltherapy for the treatment of cutaneous T-cell lymphoma.Am JHealth Syst Pharm,2010;67(10):793-797.
  • 9Sakajiri S,Kumagai T,Kawamata N,et al.Histone deacetylaseinhibitors profoundly decrease proliferation of human lymphoidcancer cell lines.Exp Hematol;2005,33(1):53-61.
  • 10Zhao WL,Wang L,Liu YH,et al.Combined effects of histonedeacetylase inhibitor and rituximab on non-Hodgkin's B-lymphomacells apoptosis.Exp Hematol,2007;35(12):1801-1811.

共引文献106

同被引文献35

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部